The combination of FXR agonist PX20350 with sorafenib, a multi-kinase inhibitor against a broad range of protein kinases, reduces HCC metastasis in the lymph nodes in an orthotopic mouse xenograft model [81]. This evidence concerns the gene NR1H4 and hepatocellular carcinoma.